Biolom, Inc. produces revolutionary biosensors for diagnosis and monitoring of diseases. Our state-of-the-art technology combines modified semiconductor fabrication techniques and high-rate, large volume assembly of nanomaterials resulting in low-cost micron-scale biosensors; size of a pinhead. The biosensors are capable of detecting multiple biomarkers simultaneously with high sensitivity and high specificity. Biolom sensors use very low sample volume (finger prick amount) and have a fast assay time (1/3 of our competitors) making it attractive for potential point of care applications. These features enable detection of diseases at an early stage, and decrease the cost involved in monitoring and treatment processes, therefore potentially saving many lives and improving the overall quality of healthcare. Our prototype has been tested using animal models to monitor colorectal cancer, to detect liver cancer and cardiovascular disease biomarkers. The next phase will involve raising venture capital for conducting human clinical trials.